Ann: Voluntary Suspension, page-182

Your comment is intriguing. I'm very optimistic about this stock, but I don't believe that my attachment is particularly emotional.

What facts are you referring to? I have taken my following beliefs about the facts into consideration when investing in Resapp:

1) The already-published results from other studies support FDA approval.
2) The already-published studies will be replicated by Smartcough-C.
3) If Smartcough-C does line up with published data, the FDA will approve the product.
4) If the FDA approves the product, the product can be commercialised as currently envisaged.
5) If the FDA does not approve the product it can be commercialised in other ways.
6) Existing funds plus the potential for raising news funds is sufficient to commercialise the product.
7) The management team's track record indicates that they will be able to commercialise the product.

Am I wrong (or even "delusional") in my understanding of these facts? Which ones? Why? Are other other facts you're considering? What are they?